A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

PHASE3CompletedINTERVENTIONAL
Enrollment

739

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Urinary Bladder, Overactive
Interventions
DRUG

VESIcare®

Oral

DRUG

placebo

Oral

Trial Locations (65)

10021

New York

11551

Hewlett

12205

Albany

13057

East Syracuse

13760

Endwell

14092

Lewiston

15146

Monroeville

15401

Uniontown

19063

Media

19114

Philadelphia

20017

Washington D.C.

23294

Richmond

26506

Morgantown

27103

Winston-Salem

28025

Concord

28601

Hickory

29464

Mt. Pleasant

30005

Alpharetta

30060

Marietta

30342

Atlanta

30513

Blue Ridge

32308

Tallahassee

32607

Gainesville

33027

Pembroke Pines

33324

Plantation

33347

Boyton Beach

33761

Clearwater

33765

Clearwater

44195

Cleveland

45220

Cincinnati

48302

Bloomfield Hills

58501

Bismarck

59102

Billings

62801

Centralia

63017

Chesterfield

63117

St Louis

63128

St Louis

70461

Slidell

72025

Escondido

75751

Athens

80012

Aurora

80205

Denver

83702

Boise

84015

West Point

84403

Ogden

85032

Phoenix

85258

Scottsdale

87108

Albuquerque

90057

Los Angeles

91345

Mission Hills

91607

Valley Village

92691

Mission Viejo

93703

Fresno

93901

Salinas

94027

Atherton

95608

Carmichael

97401

Eugene

98607

Vancouver

99202

Spokane

06320

New London

06850

Norwalk

06611

Trumbull

06708

Waterbury

08648

Lawrenceville

08880

South Bound Brook

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY